Xbrane in brief
Xbrane Biopharma AB is a biotechnology company that develops biosimilars, ie. follow-up drugs on subsequently approved biological drugs that can be introduced at a lower price after the patent expires for the original drug. Xbrane has a patented platform technology that provides a lower production cost for biolological drugs compared with competing systems. Xbrane has a team with the expertise to take biosimilars from the cell line to approval with extensive collective experience from drug development. Xbrane has its head office and development lab on Campus Solna, just outside Stockholm. Xbrane has been listed on Nasdaq Stockholm since September 2019, under the ticker XBRANE.
Biological drugs have revolutionized the treatment of many diseases, for example eye diseases such as age-related macular degeneration, autoimmune diseases such as rheumatoid arthritis, psoriasis and cancer. The only problem is that they are so expensive that it creates a problem around availability. In the USA, for example, biological drugs account for 40% of the country's drug costs, while only 2% of the population take part in the treatment. This is unsustainable and inconsistent with the WHO´s Constitution which states that "... the highest attainable level of health is a human right of all individuals." The goal and meaning of our work is to bring about change and eliminate these inequalities in health globally. Xbrane is a purpose-driven organization, where this purpose permeates everything we do and gives us the inspiration and motivation to drive the development of our drug candidates forward.